| 000 | 01710 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250516221632.0 | ||
| 264 | 0 | _c20150924 | |
| 008 | 201509s 0 0 eng d | ||
| 022 | _a1476-5365 | ||
| 024 | 7 |
_a10.1038/bmt.2014.131 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aShanavas, M | |
| 245 | 0 | 0 |
_aAllogeneic hematopoietic cell transplantation for myelofibrosis using fludarabine-, intravenous busulfan- and low-dose TBI-based conditioning. _h[electronic resource] |
| 260 |
_bBone marrow transplantation _cSep 2014 |
||
| 300 |
_a1162-9 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use |
| 650 | 0 | 4 |
_aBusulfan _xadministration & dosage |
| 650 | 0 | 4 | _aCombined Modality Therapy |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHematopoietic Stem Cell Transplantation _xmethods |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPrimary Myelofibrosis _xdrug therapy |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 | _aSurvival Analysis |
| 650 | 0 | 4 |
_aTransplantation Conditioning _xmethods |
| 650 | 0 | 4 | _aTransplantation, Homologous |
| 650 | 0 | 4 |
_aVidarabine _xadministration & dosage |
| 650 | 0 | 4 |
_aWhole-Body Irradiation _xmethods |
| 700 | 1 | _aMessner, H A | |
| 700 | 1 | _aAtenafu, E G | |
| 700 | 1 | _aKim, D H | |
| 700 | 1 | _aKuruvilla, J | |
| 700 | 1 | _aLipton, J H | |
| 700 | 1 | _aUhm, J | |
| 700 | 1 | _aSeftel, M | |
| 700 | 1 | _aAlam, N | |
| 700 | 1 | _aGupta, V | |
| 773 | 0 |
_tBone marrow transplantation _gvol. 49 _gno. 9 _gp. 1162-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1038/bmt.2014.131 _zAvailable from publisher's website |
| 999 |
_c23965680 _d23965680 |
||